Perlegen Sciences, Inc. Files Registration Statement for Proposed Initial Public Offering
April 10 2006 - 11:00AM
Business Wire
Perlegen Sciences, Inc., announced today it has filed a
registration statement with the U.S. Securities and Exchange
Commission relating to the proposed initial public offering of
shares of its common stock. All shares of the common stock to be
sold in this offering will be sold by Perlegen Sciences, Inc.
Perlegen is a biopharmaceutical company developing a pipeline of
late-stage genetically targeted medicines. The company also
collaborates with pharmaceutical companies to apply genetics to
drug response and disease. Lehman Brothers Inc. and Deutsche Bank
Securities Inc. will be acting as joint book-running managers and
representatives of the underwriters and are co-managers with Piper
Jaffray & Co. and Allen & Company LLC. The numbers of
shares to be offered and the price range have not yet been
determined. This offering will be made only by means of a
prospectus. Copies of the preliminary prospectus for this offering
may be obtained, when available, from Lehman Brothers Inc., c/o ADP
Financial Services, Prospectus Fulfillment, 1155 Long Island
Avenue, Edgewood, NY 11717 or by fax at (631) 254-7268 or Deutsche
Bank Securities Inc., Attn: Prospectus Department, 1251 Avenue of
the Americas, 29th floor, New York, NY 10019 or email a request to
prospectusrequest@list.db.com. A registration statement relating to
these securities has been filed with the SEC, but it has not yet
become effective. These securities may not be sold nor may offers
to buy be accepted prior to the time that the registration
statement becomes effective. This news release shall not constitute
an offer to sell or a solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction. This news release contains certain
forward-looking statements that involve risks and uncertainties.
Forward-looking statements include Perlegen's plans to sell
securities in an initial public offering. Such statements are only
predictions and actual results may differ materially from those
anticipated in these forward-looking statements. Factors that may
cause such differences include the risk that products that appeared
promising in early research and clinical trials do not demonstrate
safety or efficacy in larger-scale clinical trials and the risk
that the company will not obtain approval to market its products.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024